Drug Approval | June 13, 2026
UK approves Wegovy pill in major shift in obesity treatment options
Approval is based on results from the phase 3 OASIS 4 clinical trial
Approval is based on results from the phase 3 OASIS 4 clinical trial
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Broadening access for children & patients with inhibitor-complicated hemophilia
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
